Analyst Reco. Iqvia Holdings Inc.

Equities

IQV

US46266C1053

Biotechnology & Medical Research

Market Closed - Nyse Other stock markets 21:00:03 13/02/2026 GMT			5-day change	1st Jan Change
166.94 ^USD	-1.13%		-10.96%	-25.94%

02-13	Novo Nordisk's Wegovy Tablet Reaches 38,000 New Prescriptions in the US	FW
02-13	Novo's Wegovy pill tracks over 38,000 prescriptions in fifth week	RE

Analyst Reco.

02-06	UBS Adjusts Price Target on IQVIA to $240 From $280, Maintains Buy Rating	MT
02-06	Leerink Partners Adjusts Price Target on IQVIA Holdings to $228 From $256, Maintains Outperform Rating	MT
02-06	Evercore ISI Adjusts Price Target on IQVIA Holdings to $225 From $250, Maintains Outperform Rating	MT
02-06	BMO Capital Adjusts Price Target on IQVIA Holdings to $250 From $260, Maintains Outperform Rating	MT
02-06	Barclays Adjusts IQVIA Price Target to $210 From $230, Maintains Equal Weight Rating	MT
02-06	JPMorgan Adjusts IQVIA Price Target to $225 From $255, Maintains Overweight Rating	MT
02-06	Citigroup Adjusts IQVIA Price Target to $200 From $230, Maintains Neutral Rating	MT
02-06	Jefferies Adjusts Price Target on IQVIA Holdings to $255 From $270, Maintains Buy Rating	MT
02-06	Stifel Adjusts Price Target on IQVIA Holdings to $220 From $273, Maintains Buy Rating	MT
02-05	IQVIA backs AI strategy as analysts question impact on business	RE
02-02	Obesity market sales potential tightens as Novo and Lilly enter new era	RE
01-23	Sector Update: Health Care Stocks Softer Late Afternoon	MT
01-22	TD Cowen Adjusts Price Target on IQVIA Holdings to $245 From $215, Maintains Hold Rating	MT
01-16	Novo's Wegovy pill makes encouraging start in weight-loss race vs Lilly	RE
01-16	Baird Adjusts Price Target on IQVIA Holdings Inc to $268 From $258, Maintains Outperform Rating	MT
01-13	Rothschild & Co Redburn Adjusts IQVIA Price Target to $287 From $254, Maintains Buy Rating	MT
01-09	Mizuho Securities Adjusts IQVIA Holdings Price Target to $266 From $250, Maintains Outperform Rating	MT
01-08	UBS Adjusts Price Target on IQVIA to $280 From $250, Maintains Buy Rating	MT
01-08	Truist Raises Price Target on IQVIA Holdings to $290 From $265, Keeps Buy Rating	MT
12-19	Deutsche Bank Adjusts Price Target on IQVIA Holdings to $250 From $235, Maintains Buy Rating	MT
12-18	Stifel Nicolaus Adjusts IQVIA Price Target to $273 From $254, Maintains Buy Rating	MT
12-15	Barclays Adjusts PT on IQVIA Holdings to $230 From $200, Maintains Equalweight Rating	MT
12-02	Morgan Stanley Raises Price Target on IQVIA Holdings to $265 From $250, Keeps Overweight Rating	MT
12-02	Jefferies Adjusts Price Target on IQVIA Holdings to $270 From $255, Maintains Buy Rating	MT
12-01	HSBC Adjusts Price Target on IQVIA Holdings Inc to $270 From $250, Maintains Buy Rating	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

Analyst Reco. Iqvia Holdings Inc.

Equities

IQV

US46266C1053

Biotechnology & Medical Research

Analyst Reco.

Filters